குறி ப்மபோர்த் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-ready GMP Facility
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-ready GMP Facility
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Boxborough Conservation Trust receives $30K donation
wickedlocal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wickedlocal.com Daily Mail and Mail on Sunday newspapers.
Stage set for Dales theatre group in first of its kind Calendar Girls: The Musical production
yorkshirepost.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yorkshirepost.co.uk Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
WATERTOWN, Mass., March 8, 2021 /PRNewswire/ Arranta Bio ( Arranta ), the leading microbiome contract development and manufacturing organization (CDMO), today announced the addition of a 130,000-square-foot facility in Boxborough, Massachusetts, to complement its existing facilities in Watertown, Massachusetts and Gainesville, Florida, bringing the total manufacturing capacity at Arranta to over 230,000 square feet. Arranta closed an oversubscribed Series B equity financing from its current investors to fund the expansion.
(PRNewsfoto/Arranta Bio)
The Boxborough site will be developed in phases, and work on the first two phases has begun. Total investment in Boxborough is expected to exceed $150 million, and with the first phases of construction underway, start-up of GMP suites is expected early in 2022. The facility will employ more than 250 people, and is designed to flexibly support clients, including dedicated lab and GMP capacity that